Tectonic Therapeutic (TECX) Competitors $17.80 +0.10 (+0.54%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TECX vs. CVAC, ELVN, CALT, DNTH, LENZ, PRAX, AMPH, PHVS, SANA, and UPBShould you be buying Tectonic Therapeutic stock or one of its competitors? The main competitors of Tectonic Therapeutic include CureVac (CVAC), Enliven Therapeutics (ELVN), Calliditas Therapeutics AB (publ) (CALT), Dianthus Therapeutics (DNTH), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), Amphastar Pharmaceuticals (AMPH), Pharvaris (PHVS), Sana Biotechnology (SANA), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Tectonic Therapeutic vs. Its Competitors CureVac Enliven Therapeutics Calliditas Therapeutics AB (publ) Dianthus Therapeutics LENZ Therapeutics Praxis Precision Medicines Amphastar Pharmaceuticals Pharvaris Sana Biotechnology Upstream Bio Tectonic Therapeutic (NASDAQ:TECX) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends. Is TECX or CVAC more profitable? CureVac has a net margin of 38.21% compared to Tectonic Therapeutic's net margin of 0.00%. CureVac's return on equity of 29.57% beat Tectonic Therapeutic's return on equity.Company Net Margins Return on Equity Return on Assets Tectonic TherapeuticN/A -30.13% -28.33% CureVac 38.21%29.57%25.41% Do insiders and institutionals believe in TECX or CVAC? 62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 38.0% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer TECX or CVAC? In the previous week, Tectonic Therapeutic had 2 more articles in the media than CureVac. MarketBeat recorded 2 mentions for Tectonic Therapeutic and 0 mentions for CureVac. Tectonic Therapeutic's average media sentiment score of 1.14 beat CureVac's score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Overall Sentiment Tectonic Therapeutic Positive CureVac Neutral Do analysts rate TECX or CVAC? Tectonic Therapeutic currently has a consensus target price of $80.29, indicating a potential upside of 351.17%. CureVac has a consensus target price of $6.83, indicating a potential upside of 26.54%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, research analysts clearly believe Tectonic Therapeutic is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tectonic Therapeutic 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88CureVac 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 Which has preferable earnings and valuation, TECX or CVAC? CureVac has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTectonic TherapeuticN/AN/A-$57.98M-$4.04-4.40CureVac$579.18M2.09$175.50M$0.965.63 Which has more volatility & risk, TECX or CVAC? Tectonic Therapeutic has a beta of 3.21, indicating that its share price is 221% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500. SummaryTectonic Therapeutic beats CureVac on 9 of the 16 factors compared between the two stocks. Get Tectonic Therapeutic News Delivered to You Automatically Sign up to receive the latest news and ratings for TECX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TECX vs. The Competition Export to ExcelMetricTectonic TherapeuticMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$332.94M$3.43B$6.17B$10.57BDividend YieldN/A2.26%5.72%4.83%P/E Ratio-4.4023.4029.6628.46Price / SalesN/A262.45491.19187.09Price / CashN/A44.5736.5560.64Price / Book1.8710.3512.026.53Net Income-$57.98M-$52.53M$3.32B$276.75M7 Day Performance3.10%0.25%0.60%0.93%1 Month Performance18.71%8.98%5.14%1.41%1 Year Performance-51.11%11.56%61.09%31.59% Tectonic Therapeutic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TECXTectonic Therapeutic2.8347 of 5 stars$17.80+0.5%$80.29+351.2%-49.6%$332.94MN/A-4.40120Positive NewsCVACCureVac3.5329 of 5 stars$5.38-0.3%$6.83+27.1%+99.3%$1.21B$579.18M5.60880ELVNEnliven Therapeutics2.2895 of 5 stars$20.26-2.0%$41.20+103.4%-29.1%$1.20BN/A-10.1450News CoverageInsider TradeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180DNTHDianthus Therapeutics2.3708 of 5 stars$36.22+5.2%$60.88+68.1%+23.5%$1.17B$6.24M-11.1580LENZLENZ Therapeutics2.3665 of 5 stars$39.19+1.5%$52.80+34.7%+24.0%$1.12BN/A-20.69110Analyst UpgradeHigh Trading VolumePRAXPraxis Precision Medicines2.4687 of 5 stars$52.79+0.9%$85.56+62.1%+145.7%$1.11B$8.55M-4.30110Analyst RevisionAMPHAmphastar Pharmaceuticals4.6165 of 5 stars$23.88+1.6%$31.60+32.4%-50.4%$1.11B$731.97M8.942,028Analyst ForecastGap DownPHVSPharvaris2.6737 of 5 stars$21.16-4.1%$32.60+54.1%+3.6%$1.10BN/A-6.2830Positive NewsHigh Trading VolumeSANASana Biotechnology2.9135 of 5 stars$4.62+6.3%$7.50+62.5%+47.5%$1.10BN/A-4.35380Positive NewsUPBUpstream Bio1.5188 of 5 stars$20.09+0.0%$53.33+165.5%-15.5%$1.08B$2.37M0.0038 Related Companies and Tools Related Companies CureVac Competitors Enliven Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Dianthus Therapeutics Competitors LENZ Therapeutics Competitors Praxis Precision Medicines Competitors Amphastar Pharmaceuticals Competitors Pharvaris Competitors Sana Biotechnology Competitors Upstream Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TECX) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthFed vs. Trump - A War With American Wealth At Stake The Fed's defiance of Trump thickens the plot to contro...American Hartford Gold | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUrgent Buy Alert: My Top Three Quantum Computing StocksQuantum computing is the hottest tech trend of the year... With some of these stocks jumping 700%, 2,800% a...Brownstone Research | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
